Market Expectations   

TradingKey - Eli Lilly’s Q2 2025 earnings report is expected to be released before the U.S. stock market opens on August 7. Below are the market expectations for Eli Lilly’s Q2 2025 revenue and earnings per share (EPS):

· Revenue Expectation: Eli Lilly’s total revenue for Q2 2025 is projected to reach $15 billion, representing an approximate 33% increase compared to $11.3 billion in Q2 2024. This reflects continued strong growth in demand for the company’s key products in the second quarter, particularly the weight-loss drug Zepbound and the diabetes drug Mounjaro.

· EPS Expectation: Eli Lilly’s earnings per share (EPS) for Q2 2025 is expected to be $5.55, a significant increase of nearly 42% compared to $3.92 in Q2 2024.

Key Investor Focus Areas

Key Drug Sales Performance: Mounjaro and Zepbound are the core drivers of Eli Lilly’s revenue growth, with GLP-1 receptor agonist drugs performing strongly in the diabetes and weight-loss markets. In Q1 2025, their sales reached $3.84 billion and $2.31 billion, respectively, accounting for nearly half of total revenue. Investors should focus on whether Mounjaro and Zepbound sales in Q2 meet or exceed expectations, particularly in the U.S. market amid competition with Novo Nordisk’s Wegovy and Ozempic, and whether demand sustains the 45% robust growth trend from Q1.

Production Capacity and Supply Chain Updates: Eli Lilly has previously faced supply chain challenges with Mounjaro and Zepbound production, impacting sales momentum. Investors should pay attention to whether new production facilities have come online and whether the company can meet global demand. Updates on production expansion or supply chain improvements will directly affect growth prospects for the coming quarters.

Pipeline Progress: The company’s research pipeline is critical to long-term growth. Investors should particularly focus on the progress of Phase 3 trials for the oral GLP-1 receptor agonist orforglipron and the multi-receptor agonist retatrutide. Positive trial results in 2025 could serve as significant catalysts for stock price growth.

Competition: Eli Lilly faces intense competition in the weight-loss and diabetes drug markets from rivals like Novo Nordisk. Investors should monitor how the company strengthens its market share, as well as management’s commentary on pricing strategies and market trends.

Tariffs and External Factors: The Trump administration may impose tariffs on imported drugs, and Eli Lilly mentioned in its Q1 2025 earnings report that this risk could impact its financial outlook. Investors should focus on the company’s response strategies, such as increased investment in U.S. production, and the potential impact of tariffs on international market revenue.

 Get Started

Find out more